The relationship between asymptomatic organ damage, and serum soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) and Interleukin-17A (IL-17A) levels in non-diabetic hypertensive patients

BMC Nephrology

Volumn 15, Issue 1, 2014, Pages

  Ates, Ihsan ^a   Özkayar, Nihal ^a   Akyel, Fatma ^a   Topcuoglu, Canan ^a   Akyel, Serdar ^a   Barça, A Nurdan ^a   Dede, Fatih ^a  

^a ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Asymptomatic organ damage; Hypertension; Interleukin 17; Tumor necrosis factor like weak inducer of apoptosis

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIURETIC AGENT; INTERLEUKIN 17; SOLUBLE TUMOR NECROSIS FACTOR LIKE WEAK INDUCER OF APOPTOSIS; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; ANTIHYPERTENSIVE AGENT; IL17A PROTEIN, HUMAN; TNFSF12 PROTEIN, HUMAN;

ADULT; AGE; ANTIHYPERTENSIVE THERAPY; ARTERIAL WALL THICKNESS; ARTICLE; ASYMPTOMATIC DISEASE; ASYMPTOMATIC ORGAN DAMAGE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE METER; BLOOD PRESSURE MONITORING; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; HEART LEFT VENTRICLE MASS; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; PROTEIN BLOOD LEVEL; PROTEINURIA; RETINOPATHY; SYSTOLIC BLOOD PRESSURE; AGED; ALBUMINURIA; BLOOD; COMPLICATION; DIASTOLE; DISEASE COURSE; HYPERTENSIVE RETINOPATHY; HYPERTROPHY, LEFT VENTRICULAR; MIDDLE AGED; ORGAN SIZE; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; SYSTOLE;

ADULT; AGED; ALBUMINURIA; ANTIHYPERTENSIVE AGENTS; ASYMPTOMATIC DISEASES; CAROTID INTIMA-MEDIA THICKNESS; DIASTOLE; DISEASE PROGRESSION; FEMALE; HUMANS; HYPERTENSION; HYPERTENSIVE RETINOPATHY; HYPERTROPHY, LEFT VENTRICULAR; INTERLEUKIN-17; MALE; MIDDLE AGED; ORGAN SIZE; RISK FACTORS; ROC CURVE; SYSTOLE; TUMOR NECROSIS FACTORS;

EID: 84908105454     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-15-159     Document Type: Article

References (36)

1. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F, Burnier M, Ambrosioni E, Caufield M, Coca A, Olsen MH, Eur Heart J 2013 34 28 2159 2219 23771844
2. ABC of hypertension: the pathophysiology of hypertension. Beevers G, Lip GY, O'Brien E, BMJ 2001 322 7291 912 916 10.1136/bmj.322.7291.912 11302910
3. Inflammation, endothelial dysfunction, and the risk of high blood pressure: epidemiologic and biological evidence. Bautista LE, J Hum Hypertens 2003 17 4 223 230 10.1038/sj.jhh.1001537 12692566
4. Immune mechanisms in hypertension and vascular injury. Schiffrin EL, Clin Sci (Lond) 2014 126 4 267 274 10.1042/CS20130407 24144355
5. Interleukin-17 causes Rho-kinase-mediated endothelial dysfunction and hypertension. Nguyen H, Chiasson VL, Chatterjee P, Kopriva SE, Young KJ, Mitchell BM, Cardiovasc Res 2013 97 4 696 704 10.1093/cvr/cvs422 23263331
6. T lymphocytes: a role in hypertension? Schiffrin EL, Curr Opin Nephrol Hypertens 2010 19 2 181 186 10.1097/MNH.0b013e3283360a2e 20040866
7. Lower plasma soluble TWEAK concentration in patients with newly diagnosed hypertension. Karadurmus N, Tapan S, Cakar M, Naharci I, Celik T, Tasci I, Sayin S, Dogan T, Turker T, Erbil MK, Saglam K, Clin Invest Med 2012 35 1 20 E26 22309961
8. TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. Chicheportiche Y, Bourdon PR, Xu H, Hsu YM, Scott H, Hession C, Garcia I, Browning JL, J Biol Chem 1997 272 51 32401 32410 10.1074/jbc.272.51.32401 9405449
9. Full-length, membrane-anchored TWEAK can function as a juxtacrine signaling molecule and activate the NF-kappaB pathway. Brown SA, Ghosh A, Winkles JA, J Biol Chem 2010 285 23 17432 17441 10.1074/jbc.M110.131979 20385556
10. The role of TWEAK/Fn14 in cardiac remodeling. Ren MY, Sui SJ, Mol Biol Rep 2012 39 11 9971 9977 10.1007/s11033-012-1867-6 22752727
11. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, Weaver CT, Nat Immunol 2005 6 11 1123 1132 10.1038/ni1254 16200070
12. Enhancing effect of IL-17 on IL-1-induced IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokines. Chabaud M, Fossiez F, Taupin JL, Miossec P, J Immunol 1998 161 1 409 414 9647250
13. Th17 cells in human disease. Tesmer LA, Lundy SK, Sarkar S, Fox DA, Immunol Rev 2008 223 87 113 10.1111/j.1600-065X.2008.00628.x 18613831
14. Interleukin 17 in vascular inflammation. Von Vietinghoff S, Ley K, Cytokine Growth Factor Rev 2010 21 6 463 469 10.1016/j.cytogfr.2010.10.003 21075042
15. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Friedewald WT, Levy RI, Fredrickson DS, Clin Chem 1972 18 6 499 502 4337382
16. Creatinine filtration, secretion and excretion during progressive renal disease. Modification of Diet in Renal Disease (MDRD) Study Group. Levey AS, Berg RL, Gassman JJ, Hall PM, Walker WG, Kidney Int Suppl 1989 27 73 S80 2636677
17. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Devereux RB, Reichek N, Circulation 1977 55 4 613 618 10.1161/01.CIR.55.4.613 138494
18. Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging. Pignoli P, Tremoli E, Poli A, Oreste P, Paoletti R, Circulation 1986 74 6 1399 1406 10.1161/01.CIR.74.6.1399 3536154
19. Deficiency of the interleukin 17/23 axis accelerates renal injury in mice with deoxycorticosterone acetate + angiotensin ii-induced hypertension. Krebs CF, Lange S, Niemann G, Rosendahl A, Lehners A, Meyer-Schwesinger C, Stahl RA, Benndorf RA, Velden J, Paust HJ, Panzer U, Ehmke H, Wenzel UO, Hypertension 2014 63 3 565 571 10.1161/HYPERTENSIONAHA.113.02620 24366079
20. TWEAK/Fn14 pathway: an immunological switch for shaping tissue responses. Burkly LC, Michaelson JS, Zheng TS, Immunol Rev 2011 244 1 99 114 10.1111/j.1600-065X.2011.01054.x 22017434
21. Soluble TWEAK is markedly upregulated in patients with ST-elevation myocardial infarction and related to an adverse short-term outcome. Chorianopoulos E, Jarr K, Steen H, Giannitsis E, Frey N, Katus HA, Atherosclerosis 2010 211 1 322 326 10.1016/j.atherosclerosis.2010.02.016 20303491
22. Decreased soluble TWEAK levels predict an adverse prognosis in patients with chronic stable heart failure. Chorianopoulos E, Rosenberg M, Zugck C, Wolf J, Katus HA, Frey N, Eur J Heart Fail 2009 11 11 1050 1056 10.1093/eurjhf/hfp139 19875405
23. Circulating sTWEAK improves the prediction of coronary artery disease. Jelic-Ivanovic Z, Bujisic N, Spasic S, Bogavac-Stanojevic N, Spasojevic-Kalimanovska V, Kotur-Stevuljevic J, Clin Biochem 2009 42 13-14 1381 1386 19505454
24. Soluble TWEAK plasma levels as a novel biomarker of endothelial function in patients with chronic kidney disease. Yilmaz MI, Carrero JJ, Ortiz A, Martin-Ventura JL, Sonmez A, Saglam M, Yaman H, Yenicesu M, Egido J, Blanco-Colio LM, Clin J Am Soc Nephrol 2009 4 11 1716 1723 10.2215/CJN.02760409 19820131
25. Soluble TWEAK independently predicts atherosclerosis in renal transplant patients. Turkmen K, Tonbul HZ, Erdur FM, Toker A, Biyik Z, Ozbiner H, Gaipov A, Gul EE, Kayrak M, Solak Y, Ozbek O, Turk S, Covic A, BMC Nephrol 2013 14 144 10.1186/1471-2369-14-144 23849432
26. TWEAK: a new player in obesity and diabetes. Vendrell J, Chacon MR, Front Immunol 2013 4 488 24416031
27. The CD163-expressing macrophages recognize and internalize TWEAK: potential consequences in atherosclerosis. Moreno JA, Munoz-Garcia B, Martin-Ventura JL, Madrigal-Matute J, Orbe J, Paramo JA, Ortega L, Egido J, Blanco-Colio LM, Atherosclerosis 2009 207 1 103 110 10.1016/j.atherosclerosis.2009.04.033 19473660
28. TWEAK-Fn14 cytokine-receptor axis: a new player of myocardial remodeling and cardiac failure. Novoyatleva T, Sajjad A, Engel FB, Front Immunol 2014 5 50 24611063
29. Fn14 in podocytes and proteinuric kidney disease. Sanchez-Nino MD, Poveda J, Sanz AB, Mezzano S, Carrasco S, Fernandez-Fernandez B, Burkly LC, Nair V, Kretzler M, Hodgin JB, Nair V, Kretzler M, Hodgin JB, Ruiz-Ortega M, Selgas R, Egido J, Ortiz A, Biochim Biophys Acta 2013 1832 2232 2243 10.1016/j.bbadis.2013.08.010 23999007
30. Interleukin-17 in atherosclerosis and cardiovascular disease: the good, the bad, and the unknown. Liuzzo G, Trotta F, Pedicino D, Eur Heart J 2013 34 8 556 559 10.1093/eurheartj/ehs399 23178645
31. Interleukin 17 promotes angiotensin II-induced hypertension and vascular dysfunction. Madhur MS, Lob HE, McCann LA, Iwakura Y, Blinder Y, Guzik TJ, Harrison DG, Hypertension 2010 55 2 500 507 10.1161/HYPERTENSIONAHA.109.145094 20038749
32. Correlation of peripheral Th17 cells and Th17-associated cytokines to the severity of carotid artery plaque and its clinical implication. Liu Z, Lu F, Pan H, Zhao Y, Wang S, Sun S, Li J, Hu X, Wang L, Atherosclerosis 2012 221 1 232 241 10.1016/j.atherosclerosis.2011.12.026 22265273
33. Soluble tumor necrosis factor-like weak inducer of apoptosis plasma levels as a novel biomarker of endothelial function in prevalent orthotopic heart transplant recipients. Przybylowski P, Malyszko JS, Malyszko J, Transplant Proc 2011 43 5 1900 1903 10.1016/j.transproceed.2011.03.040 21693297
34. Inflammation and apoptosis in hypertension. Relevance of the extent of target organ damage. Morillas P, de Andrade H, Castillo J, Quiles J, Bertomeu-Gonzalez V, Cordero A, Tarazon E, Rosello E, Portoles M, Rivera M, Bertomeu-Martinez V, Rev Esp Cardiol 2012 65 9 819 825 10.1016/j.recesp.2012.03.020 22771083
35. C-reactive protein and target organ damage in untreated patients with primary hypertension. Ratto E, Leoncini G, Viazzi F, Falqui V, Parodi A, Conti N, Tomolillo C, Deferrari G, Pontremoli R, J Am Soc Hypertens 2007 1 6 407 413 10.1016/j.jash.2007.09.003 20409873
36. Association between serum uric acid levels and coronary flow reserve in hypertensive patients without concomitant risk factors. Caliskan M, Erdogan D, Gullu H, Yildirim I, Ozer I, Yildirir A, Muderrisoglu H, Blood Press 2007 16 4 254 261 10.1080/08037050701428240 17852089